Cannara Biotech Stock Performance
| LOVFF Stock | USD 0.58 0.01 1.75% |
On a scale of 0 to 100, Cannara Biotech holds a performance score of 7. The firm shows a Beta (market volatility) of 0.0524, which signifies not very significant fluctuations relative to the market. As returns on the market increase, Cannara Biotech's returns are expected to increase less than the market. However, during the bear market, the loss of holding Cannara Biotech is expected to be smaller as well. Please check Cannara Biotech's treynor ratio and the relationship between the downside variance and day typical price , to make a quick decision on whether Cannara Biotech's price patterns will revert.
Risk-Adjusted Performance
7 of 100
Weak | Strong |
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Cannara Biotech are ranked lower than 7 (%) of all global equities and portfolios over the last 90 days. Despite nearly fragile technical and fundamental indicators, Cannara Biotech reported solid returns over the last few months and may actually be approaching a breakup point. ...more
| Begin Period Cash Flow | 8.2 M | |
| Total Cashflows From Investing Activities | -15.3 M |
Cannara |
Cannara Biotech Relative Risk vs. Return Landscape
If you would invest 47.00 in Cannara Biotech on October 25, 2024 and sell it today you would earn a total of 11.00 from holding Cannara Biotech or generate 23.4% return on investment over 90 days. Cannara Biotech is currently producing 0.5147% returns and takes up 5.7679% volatility of returns over 90 trading days. Put another way, 51% of traded otc stocks are less volatile than Cannara, and 90% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Cannara Biotech Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Cannara Biotech's investment risk. Standard deviation is the most common way to measure market volatility of otc stocks, such as Cannara Biotech, and traders can use it to determine the average amount a Cannara Biotech's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0892
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | LOVFF | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 5.77 actual daily | 51 51% of assets are less volatile |
Expected Return
| 0.51 actual daily | 10 90% of assets have higher returns |
Risk-Adjusted Return
| 0.09 actual daily | 7 93% of assets perform better |
Based on monthly moving average Cannara Biotech is performing at about 7% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Cannara Biotech by adding it to a well-diversified portfolio.
Cannara Biotech Fundamentals Growth
Cannara OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Cannara Biotech, and Cannara Biotech fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Cannara OTC Stock performance.
| Return On Equity | 0.0434 | |||
| Return On Asset | 0.0327 | |||
| Profit Margin | 0.07 % | |||
| Operating Margin | 0.15 % | |||
| Current Valuation | 94.03 M | |||
| Shares Outstanding | 877.48 M | |||
| Price To Earning | 85.00 X | |||
| Price To Book | 1.37 X | |||
| Price To Sales | 1.81 X | |||
| Revenue | 35.84 M | |||
| EBITDA | 8.14 M | |||
| Cash And Equivalents | 3.88 M | |||
| Total Debt | 46.19 M | |||
| Debt To Equity | 0.49 % | |||
| Book Value Per Share | 0.08 X | |||
| Cash Flow From Operations | (6.08 M) | |||
| Earnings Per Share | 0.15 X | |||
| Total Asset | 125.62 M | |||
About Cannara Biotech Performance
By analyzing Cannara Biotech's fundamental ratios, stakeholders can gain valuable insights into Cannara Biotech's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Cannara Biotech has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Cannara Biotech has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Cannara Biotech Inc., together with its subsidiaries, engages in the indoor cultivation, processing, and sale of cannabis and cannabis-infused products in Canada. The company was incorporated in 2017 and is headquartered in Saint-Laurent, Canada. Cannara Biotech is traded on OTC Exchange in the United States.Things to note about Cannara Biotech performance evaluation
Checking the ongoing alerts about Cannara Biotech for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Cannara Biotech help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Cannara Biotech is way too risky over 90 days horizon | |
| Cannara Biotech has some characteristics of a very speculative penny stock | |
| Cannara Biotech appears to be risky and price may revert if volatility continues | |
| Cannara Biotech has accumulated about 3.88 M in cash with (6.08 M) of positive cash flow from operations. | |
| Roughly 48.0% of the company outstanding shares are owned by corporate insiders |
- Analyzing Cannara Biotech's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Cannara Biotech's stock is overvalued or undervalued compared to its peers.
- Examining Cannara Biotech's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Cannara Biotech's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Cannara Biotech's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Cannara Biotech's otc stock. These opinions can provide insight into Cannara Biotech's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Cannara OTC Stock analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios |